Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Post by mrmomoon Aug 03, 2021 10:39am
396 Views
Post# 33642068

For God's sake....WHY?

For God's sake....WHY?Why are some folks like Woundedknee, who's name a recognise from the O&G boards btw, taking such a HUGE risk & committing large sums of money to VERY specualtive garbage like Antibe? I've been investing for over several decades, many years of it in the BioTech sector and let me tell you this.....for those that aren't THAT aware. The chances that a very speculative play like Antibe is successfull in developping a treatment/medication/cure for some type of disease or medical condition is VERY remote......at best. This doesn't even take into account the fact that the odds get much worse because it has to get FDA approval EVEN if the drug is proven to work. Which is a monumental task in itself which takes MANY years & a lot of money. Don't know about some folks, but it's already bad enough to invest in risky American or European Biotech firms, which at least have the funds, the staff & connections to have at least a SMALL chance to succeed in this whole process. Why would ANYONE invest in a VERY specualtive Canadian biotech firm which doesn't have ANY of those above resources in sufficient abundance or quality?

I offer ONLY two pieces of good advice for  folks looking to invest in this sector. One, be prepared for a VERY LONG and arduous experiece & investment time frame. Two, don't bother & AVOID the Canadian space for this sector, they just don't have what it takes to even have a CHANCE to succeed. In other words, you don't go to Africa to have heart surgery, you go where you know there's a chance, limit the risk & you have the knowhow to avoid total faliure. For Canadian investing, stick to banks & resource.....nothing else. For Tech & Biotech you with the best......American, Japanese & Europeans firms. Do this and i guranatee you'll lower your risk of failure and avoid the pitfalls that befell folks like Woundedknee. Who probably just blew ALL his gains for the last few years he made in the O&G sector. Wounded, i hope you can recover my friend......

Good luck & Godspeed
<< Previous
Bullboard Posts
Next >>